Dosage Forms

Articles

Participants in two dosing cohorts in Moderna’s mRNA-1273 study reached or exceeded neutralizing antibody titers generally seen in convalescent sera.

mRNA Vaccine Shows Positive Interim Phase I Results

The Coalition for Epidemic Preparedness Innovations will invest up to $384 million of additional funding, in addition to the $4 million it invested in March, to advance the clinical development of NVX-CoV2373, Novavax’s COVID-19 vaccine candidate.

Novavax to Receive up to $384 Million in Funding from CEPI for COVID-19 Vaccine Candidate

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

Will moving at “warp speed” to develop a vaccine impact efficacy or safety?

How Fast Is Too Fast?

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Equipment and process optimization must be considered for scaling up these developmental technologies to commercial production.

Manufacturing Microneedle Array Patches for Vaccine Delivery

The goal of the collaboration is to manufacture up to one billion does per year of mRNA-1273, Moderna’s vaccine against the novel coronavirus.

Lonza, Moderna Form Global Collaboration to Manufacture Moderna’s COVID-19 Vaccine

AstraZeneca and the University of Oxford have announced that they will collaborate on the global development and distribution of the university’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection.

AstraZeneca, University of Oxford Collaborate on COVID-19 Vaccine

Merck will provide funding and will work with researchers at the Institute for Systems Biology to identify targets for therapeutic intervention and vaccine development.

Merck Enters into Research Collaboration with the Institute for Systems Biology for COVID-19 Medicines and Vaccines

A UK BioIndustry Association industry-led vaccine manufacturing group has welcomed a recent announcement by the government of the UK, that it will receive £14 million (US$17.3 million) in investment to rapidly scale up the development of vaccines for COVID-19.


Industry-Led Manufacturing Group Welcomes UK Government Investment

The vaccine will be based on a ReiThera-proprietary simian adenoviral vector with strong immunological potency and low pre-existing immunity in humans.

ReiThera, Leukocare, and Univercells Collaborate for COVID-19 Vaccine Development

Emergent will offer up its drug substance manufacturing services with support by investments from Johnson & Johnson starting in 2020.